Sodium oxybate for the treatment of narcolepsy

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Narcolepsy, a lifelong disease with diverse symptoms, poses a therapeutic challenge to physicians. Psychomotor stimulants are used to provide some relief from excessive sleepiness, whereas a variety of other medications have traditionally been used to treat the other symptoms of this disorder. Cataplexy, consisting of sudden episodes of bilateral skeletal muscle weakness, has long been treated with tricyclic antidepressants or selective serotonin reuptake inhibitors. Although these drugs have brought relief to some patients, they cause intolerable adverse effects in others, whereas still others become tolerant to their beneficial effects. In July of 2002, sodium oxybate was approved by the US FDA for the treatment of cataplexy, representing a significant advance in the treatment of this unusual disease. The following drug evaluation summarises the role of this novel medication in the practice of sleep medicine.

Original languageEnglish (US)
Pages (from-to)329-335
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume6
Issue number2
DOIs
StatePublished - Feb 2005

Fingerprint

Sodium Oxybate
Narcolepsy
Cataplexy
Drug Evaluation
Tricyclic Antidepressive Agents
Muscle Weakness
Serotonin Uptake Inhibitors
Sleep
Skeletal Muscle
Therapeutics
Medicine
Physicians
Pharmaceutical Preparations

Keywords

  • Cataplexy
  • Gamma-hydroxybutyrate
  • Narcolepsy
  • Pharmacotherapy
  • Sodium oxybate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Sodium oxybate for the treatment of narcolepsy. / Thorpy, Michael J.

In: Expert Opinion on Pharmacotherapy, Vol. 6, No. 2, 02.2005, p. 329-335.

Research output: Contribution to journalArticle

@article{b0e1aab0f1a546eeb7b9c762defae10f,
title = "Sodium oxybate for the treatment of narcolepsy",
abstract = "Narcolepsy, a lifelong disease with diverse symptoms, poses a therapeutic challenge to physicians. Psychomotor stimulants are used to provide some relief from excessive sleepiness, whereas a variety of other medications have traditionally been used to treat the other symptoms of this disorder. Cataplexy, consisting of sudden episodes of bilateral skeletal muscle weakness, has long been treated with tricyclic antidepressants or selective serotonin reuptake inhibitors. Although these drugs have brought relief to some patients, they cause intolerable adverse effects in others, whereas still others become tolerant to their beneficial effects. In July of 2002, sodium oxybate was approved by the US FDA for the treatment of cataplexy, representing a significant advance in the treatment of this unusual disease. The following drug evaluation summarises the role of this novel medication in the practice of sleep medicine.",
keywords = "Cataplexy, Gamma-hydroxybutyrate, Narcolepsy, Pharmacotherapy, Sodium oxybate",
author = "Thorpy, {Michael J.}",
year = "2005",
month = "2",
doi = "10.1517/14656566.6.2.329",
language = "English (US)",
volume = "6",
pages = "329--335",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Sodium oxybate for the treatment of narcolepsy

AU - Thorpy, Michael J.

PY - 2005/2

Y1 - 2005/2

N2 - Narcolepsy, a lifelong disease with diverse symptoms, poses a therapeutic challenge to physicians. Psychomotor stimulants are used to provide some relief from excessive sleepiness, whereas a variety of other medications have traditionally been used to treat the other symptoms of this disorder. Cataplexy, consisting of sudden episodes of bilateral skeletal muscle weakness, has long been treated with tricyclic antidepressants or selective serotonin reuptake inhibitors. Although these drugs have brought relief to some patients, they cause intolerable adverse effects in others, whereas still others become tolerant to their beneficial effects. In July of 2002, sodium oxybate was approved by the US FDA for the treatment of cataplexy, representing a significant advance in the treatment of this unusual disease. The following drug evaluation summarises the role of this novel medication in the practice of sleep medicine.

AB - Narcolepsy, a lifelong disease with diverse symptoms, poses a therapeutic challenge to physicians. Psychomotor stimulants are used to provide some relief from excessive sleepiness, whereas a variety of other medications have traditionally been used to treat the other symptoms of this disorder. Cataplexy, consisting of sudden episodes of bilateral skeletal muscle weakness, has long been treated with tricyclic antidepressants or selective serotonin reuptake inhibitors. Although these drugs have brought relief to some patients, they cause intolerable adverse effects in others, whereas still others become tolerant to their beneficial effects. In July of 2002, sodium oxybate was approved by the US FDA for the treatment of cataplexy, representing a significant advance in the treatment of this unusual disease. The following drug evaluation summarises the role of this novel medication in the practice of sleep medicine.

KW - Cataplexy

KW - Gamma-hydroxybutyrate

KW - Narcolepsy

KW - Pharmacotherapy

KW - Sodium oxybate

UR - http://www.scopus.com/inward/record.url?scp=14544307388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14544307388&partnerID=8YFLogxK

U2 - 10.1517/14656566.6.2.329

DO - 10.1517/14656566.6.2.329

M3 - Article

VL - 6

SP - 329

EP - 335

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 2

ER -